Biochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia

Multivariable regression analyses were performed for s-K, s-Na, fractional excretion (FE)-K, FE-Cl, FE-H₂O and serum urea (s-urea) as dependent variables to assess associations with spironolactone while accounting for potential confounders.</p> <p>After eGFR adjustment, spironolactone users showed higher s-K (<i>p</i><0.001), s-urea (<i>p</i><0.001) and s-uric acid (s-UA; <i>p</i>=0.01). The spironolactone-alone group showed higher s-K (<i>p</i>=0.003), and s-urea (<i>p</i>=0.001) compared to the non-diuretic group; lower dose (<i>p</i>=0.04), s-urea (<i>p</i>=0.04), serum creatinine (s-creatinine) (<i>p</i><0.001), s-UA (<i>p</i>=0.02) and chronic heart failure prevalence (<i>p</i><0.001); higher eGFR (<i>p</i>=0.002), and hypertension prevalence (<i>p</i>=0.048), compared to the spironolactone+furosemide group.

Multivariable regression analyses identified independent associations of spironolactone with higher s-K (<i>b</i>=0.33, <i>p</i>=0.001) and with higher log-transformed s-urea (<i>b</i>=0.22, <i>p</i><0.001), corresponding to a 24.5% increase in s-urea.</p> <p>Spironolactone was independently associated with higher s-K and with higher s-urea levels. This pattern was not reflected by reduced urinary potassium excretion. Importantly, no clear evidence that concomitant furosemide materially modified this biochemical pattern was observed in the present analyses.

Awareness of this pattern may support the phenotypic characterization of hyponatraemic patients receiving spironolactone. However, prospective studies are warranted to evaluate the diagnostic utility of this biochemical pattern in hyponatraemic patients receiving spironolactone.</p>